Biotechnology

Nascent Biotech Commencing Enrollment of Second Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

June 8, 2021 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / June 8, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce the beginning of enrollment of the second cohort in dosing patients for its Phase I trial for Brain Cancer. This milestone allows the trial to...

Read more

heliosDX and RushNet Inc. Sign Binding Letter of Intent to Acquire Laboratory and Target Additional Laboratory Acquisitions

June 7, 2021 8:00 AM

ALPHARETTA, GA / ACCESSWIRE / June 7, 2021 / RushNet, Inc (OTC PINK:RSHN) ("RushNet") with merger/acquisition target heliosDX, is pleased to announce a Binding Letter of Intent by heliosdDX to acquire a privately held laboratory with $10,000,000 annual revenues processing more than 5,000 tests monthly with a capacity of 12,000 monthly UDS tests. The acquisition further increases the National footprint of heliosDX while also reducing costs,...

Read more

BioLargo (BLGO) to Present at LD Micro Invitational XI

June 4, 2021 8:30 AM

Presentation on Wednesday, June 9 at 5:00 PM ET WESTMINSTER, CA / ACCESSWIRE / June 4, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced today that it will be giving an investor presentation at the upcoming LD Micro virtual event on Wednesday, June 9, 2021, at 5:00 PM ET. BioLargo President and CEO Dennis P. Calvert will be giving the...

Read more

CEO Of Aqualung Therapeutics Corp., Joe G.N. Garcia MD, Named Invited Speaker at the First Annual Acute Respiratory Distress Syndrome Drug Development Summit

June 3, 2021 10:15 AM

TUCSON, AZ / ACCESSWIRE / June 3, 2021 / Aqualung Therapeutics, an early-stage biotech company developing an immune-focused, anti-inflammatory therapeutic platform for unchecked inflammation, a characteristic of serious acute and chronic diseases, will be participating in the first annual Acute Respiratory Distress Syndrome (ARDS) Drug Development Summit from July 13th-15th. This virtual summit includes several of the world's top experts on ARDS...

Read more

Applied UV Sign Exclusive Distribution Agreement with Vietnam Distributor for Airocide(R) Air Purification Systems

June 3, 2021 8:30 AM

Distributor will provide fast access to a high growth market MOUNT VERNON, NY / ACCESSWIRE / June 3, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced that today...

Read more

Edesa Biotech Reports Positive Interim Results in Dermatitis Trial

June 3, 2021 7:30 AM

TORONTO, ON / ACCESSWIRE / June 3, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's drug candidate EB01 has met a key interim study parameter. The company has now passed the initial inflection point of its Phase2b study and will continue enrolling the final cohort of patients. Edesa reported that interim study data from...

Read more

Lesotho Government Supports M2Bio Sciences Blockchain Initiatives

June 2, 2021 9:35 AM

CAPE TOWN, SA / ACCESSWIRE / June 2, 2021 / WUHAN GENERAL GROUP, INC. (WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update: The Lesotho Government has lent its official support to two blockchain initiatives being implemented by M2Bio Sciences. This was confirmed in a letter written to M2Bio Sciences CEO Jeff Robinson by...

Read more

Applied UV's Airocide(R) System Installed in Judges Rooms to Protect Participants at the 28th Grand International Wine Award "MUNDUS VINI" 2021

June 2, 2021 8:30 AM

Installation of Fifty Airocide® Systems Highlights Growing Demand for Better Air Quality at Live Indoor Events Leveraging industry recognition to expand market share in rapidly growing wine industry Airocide® Named Official Partner of "MUNDUS VINI" 2021 MOUNT VERNON, NY / ACCESSWIRE / June 2, 2021 / Applied UV, Inc. (NasdaqCM:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of...

Read more

GeneCentric Therapeutics Announces Presentations at Upcoming American Society of Clinical Oncology (ASCO) Annual Meeting

June 2, 2021 8:00 AM

Ongoing Collaboration with Basilea Pharmaceutica International Ltd and their Lisavanbulin Clinical Program in Glioblastoma Will Be Highlighted at ASCO DURHAM, NC / ACCESSWIRE / June 2, 2021 / GeneCentric Therapeutics, a company making precision medicine more precise, today announced upcoming data presentations at the American Society of Clinical Oncology (ASCO) annual meeting, being held virtually June 4th through 8th. The presentations will...

Read more

HAVN Life Completes Acquisition of Clinical Stage IP for Development of Cluster Headache Drug

June 2, 2021 8:00 AM

The Company will seek Orphan Drug Designation to significantly reduce time to market VANCOUVER, BC / ACCESSWIRE / June 2, 2021 / HAVN Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "HAVN Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce the completion of the previously announced acquisition of clinical...

Read more

Hillstream BioPharma Announces Abstract at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting HSB-1216’s Effect in Triple Negative Breast Cancer (TNBC)

June 2, 2021 8:00 AM

HSB-1216 and a Novel Anthracycline, Pirarubicin, Combined and Targeted Using Quatramer Shows Synergistic Effect in TNBC BRIDGEWATER, NJ / ACCESSWIRE / June 2, 2021 / Hillstream BioPharma, Inc. ("Hillstream") today announced that an abstract highlighting the progress of HSB-1216 pipeline candidate is being presented as an online publication only at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from June 4-8,...

Read more

Health Canada Accepts New Drug Submission for REDUVO(TM) as a Treatment for Patients with Chemotherapy-induced Nausea and Vomiting

June 2, 2021 7:30 AM

This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 28, 2021 to its short form base shelf prospectus dated April 1, 2020 The Company approaches a significant milestone advancing from a pre-revenue biotech to in revenue OTTAWA, ON / ACCESSWIRE / June 2, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in...

Read more

Apollo Endosurgery to Present at June Investor Conferences

June 1, 2021 12:00 PM

AUSTIN, TX / ACCESSWWIRE / June 1, 2021 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures today announced that management will participate in two investor conference events during the month of June 2021. Conferences Apollo Endosurgery management will participate include: Wednesday, June 2, 2021 18th Annual Craig-Hallum Institutional...

Read more

Applied UV’s Airocide(TM) System Installed in Uruguayan School System

June 1, 2021 8:30 AM

60 Airocide® Units now operating in Colegio Santa Elena Installation is expected to be first of many as international expansion strategy accelerates Installation in school system follows recently awarded $3.5 million minimum first year purchase commitment to Applied UV from South Africa distributor MOUNT VERNON, NY / ACCESSWIRE / June 1, 2021 / Applied UV, Inc. (NasdaqCM:AUVI) ("Applied UV" or the "Company"), an infection control...

Read more

Thermic Science Proudly Receives OTC Markets Registration Confirmation, Makes Payment of Initial Exchange Fees to Begin Uploading its Financials and Reporting Requirements to Bring the Company Current and in Compliance with the Amended Rule 15c2-11

June 1, 2021 7:05 AM

NASHVILLE, TN / ACCESSWIRE / June 1, 2021 / Thermic Science International Corporation, formerly known as Omnicanna Health Solutions, Inc. aka Endocan Corporation. (WKN:A1W61J) (ISIN:US29271J1097) (OTC PINK:ENDO), is proud to announce it has officially received OTC Markets registration confirmations, completing its new OTC Markets registration ready to upload all newly updated State of Nevada registered corporate information. Thermic Science...

Read more

World Class Provides Pineapple Express Delivery Revenue Update

June 1, 2021 3:30 AM

Pineapple Express Delivery's revenue total $2.77M January - April 2021 VANCOUVER, BC / ACCESSWIRE / June 1, 2021 / World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) ("Company" or "World-Class"), is pleased to provide an update on Pineapple Express Delivery Inc. ("Pineapple Express Delivery" or "PED"), a company in which World-Class has a controlling interest. PED is a leading logistics technology company offering compliant and...

Read more

Experion Reports on AGM Results

May 31, 2021 8:45 AM

VANCOUVER, BC / ACCESSWIRE / May 31, 2021 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) is pleased to announce the results of its annual general and special meeting of the shareholders held by way of live virtual webcast on May 26, 2021 (the "Meeting"). All of the matters put forward before shareholders for consideration and approval as set out in Experion's notice of meeting were approved by...

Read more

Edesa Biotech to Join Panel Discussion at Industry Event

May 28, 2021 8:00 AM

TORONTO, ON / ACCESSWIRE / May 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to participate in a virtual event organized by the Ontario Bioscience Innovation Organization. As part of a panel of health science and investment professionals, Dr. Nijhawan is expected to discuss publicly available information regarding Edesa and...

Read more

Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19

May 27, 2021 1:15 AM

EMPATHY global multi-center Phase 2 - 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalization The study plans to enroll 2100 patients, with 400 patients to be enrolled into Phase 2, followed by 1700 patients in Phase 3 Novartis has been granted an option from Molecular Partners to in-license global rights of ensovibep and MP0423 - DARPin® antiviral therapeutic...

Read more

Enzolytics Announces the Discovery of Conserved, Immutable Target Sites on HTLV-1 and Plans To Commence Production of Monoclonal Antibodies Targeting These Sites

May 26, 2021 7:30 AM

COLLEGE STATION, TX / ACCESSWIRE / May 26, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") today announced it has identified conserved, expectedly immutable sites on the HTLV-1 virus against which it will produce targeted anti-HTLV-1 monoclonal antibodies (mAbs). There are no effective vaccines against HTLV-1 and no antiviral drugs available for treating infections caused by the virus. Utilizing the Company's proprietary Artificial...

Read more